Marta A. Crispens

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial”.

Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

The Lancet Oncology(2020)10.1016/s1470-2045(20)30180-7

N/A

5.1DataRank · unranked

233 citations

Su-Chun Cheng, Andrea E. Wahner Hendrickson, Richard T. Penson, Susan Schumer, L. Austin Doyle +19 more

Expression of p52, a non-canonical NF-kappaB transcription factor, is associated with poor ovarian cancer prognosis

Biomarker Research(2020)10.1186/s40364-020-00227-y

N/A

0DataRank · unranked

11 citations

Andrew J. Wilson, Jamie A. Saxon, Timothy S. Blackwell, Jaclyn C. Watkins, Dineo Khabele +4 more

CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.01.038

N/A

0DataRank · unranked

42 citations

Andrew J. Wilson, Jeff Hirst, Katherine F. Roby, Oluwole Fadare, Marta A. Crispens +3 more

Increased canonical NF-kappaB signaling specifically in macrophages is sufficient to limit tumor progression in syngeneic murine models of ovarian cancer

BMC Cancer(2020)10.1186/s12885-020-07450-8

N/A

0DataRank · unranked

32 citations

Demetra Hufnagel, Whitney R. Harris, Kennady K. Bullock, Evan B. Glass, Esther Liu +7 more

Increasing Area Deprivation Index negatively impacts ovarian cancer survival

Cancer Epidemiology(2021)10.1016/j.canep.2021.102013

N/A

0DataRank · unranked

47 citations

Dineo Khabele, Fiona E. Yull, Pamela C. Hull, Joellen M. Schildkraut, Marta A. Crispens +2 more

Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer

Neoplasia(2021)10.1016/j.neo.2021.12.002

N/A

0DataRank · unranked

29 citations

Vijayalaxmi Gupta, Qi Liu, Fiona E. Yull, Marta A. Crispens, Dineo Khabele +1 more

Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer

BMC Cancer(2022)10.1186/s12885-022-09612-2

N/A

0DataRank · unranked

32 citations

Alyssa Hoover, Kennady K. Bullock, Matthew Z. Madden, Bradley I. Reinfeld, Whitney R. Harris +10 more

A randomized phase II study of bevacizumab and weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or refractory ovarian cancer NCI trial#10150.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.5514

N/A

0DataRank · unranked

22 citations

Husam Alqaisi, David E. Cohn, Jing‐Yi Chern, Linda Duska, Andrea Jewell +15 more

COVID-19 in patients with gynecologic cancer: A preliminary report from the COVID-19 and Cancer Consortium (CCC19).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.5508

N/A

0DataRank · unranked

0 citations

Lauren S. Prescott, Erika Ruíz‐García, Clara Hwang, Hannah Heilman, Rana R. McKay +13 more

Tumor therapy by targeting extracellular hydroxyapatite using novel drugs: A paradigm shift

Cancer Medicine(2024)10.1002/cam4.6812

N/A

0DataRank · unranked

3 citations

J. Oliver McIntyre, Fiona E. Yull, M. Wade Calcutt, Dmitry S. Koktysh, Andrew J. Wilson +12 more